| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Rein Therapeutics, Inc. (RNTX) has 6 insiders with recent SEC Form 4 filings, including 4 buys and 0 sells. RNTX is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 926.4K | $837.4K | - | |
| Dir | 17.5K | $15.8K | - | |
| Dir | 17.5K | $15.8K | - | |
| Dir | 17.5K | $15.8K | - | |
| Dir | 17.5K | $15.8K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jul 5, 2017 | Excel Medical Fund LP | 10% Owner | Buy | 60,000 | $15.00 | $900,000.00 | +6.3% | |
| Jul 5, 2017 | Sigma Emerging Markets Ltd. | 10% Owner | Buy | 190,000 | $15.00 | $2,850,000.00 | +81.5% | |
| Jul 5, 2017 | Gallagher Brian M. Jr. | Director | Buy | 273,333 | $15.00 | $4,099,995.00 | +23.6% | |
| Jul 5, 2017 | Ambros Reinhard J. | Director | Buy | 266,667 | $15.00 | $4,000,005.00 | +11.7% |